Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Real-Time Price · USD

24.18

-1.59 (-6.17%)

Feb 4, 2026, 4:00 PM EST - Market closed

Lyell Immunopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 4, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	514	187	489	865	1,861	-
Market Cap Growth	209.05%	-61.73%	-43.52%	-53.52%	-	-
Enterprise Value	238	-215	-45	182	992	-
Last Close Price	24.18	12.80	38.80	69.40	154.80	-
PS Ratio	12528.75	3065.30	3758.66	10.22	174.77	-
PB Ratio	1.42	0.49	0.75	1.04	2.00	-
P/TBV Ratio	1.56	0.49	0.75	1.04	2.00	-
EV/Sales Ratio	5813.17	-	-	2.15	93.15	-
Debt / Equity Ratio	0.14	0.15	0.10	0.08	0.07	0.08
Asset Turnover	0	0	0	0.08	0.01	0.01
Quick Ratio	10.03	6.89	15.82	17.29	13.15	12.43
Current Ratio	10.30	7.06	16.07	17.59	13.40	12.53
Return on Equity (ROE)	-75.75%	-66.10%	-31.53%	-20.77%	-30.36%	-36.30%
Return on Assets (ROA)	-24.16%	-22.05%	-18.18%	-11.32%	-13.11%	-18.76%
Return on Capital Employed (ROCE)	-52.80%	-50.10%	-34.30%	-20.80%	-19.80%	-25.60%
Earnings Yield	-63.40%	-183.44%	-48.02%	-21.17%	-13.44%	-
FCF Yield	-32.23%	-87.10%	-34.05%	-22.40%	-10.30%	-
Buyback Yield / Dilution	-21.43%	-4.18%	-1.58%	-81.79%	-925.18%	-144.21%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q